Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy

FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)

Trial Details

NCT ID
NCT03581773
Phase
PHASE2
Sponsor
Niels Fristrup
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Folic Acid
  • Placebo Oral Tablet
Locations (sample)
  • Aarhus, Central Region of Denmark, Denmark|56.15674,10.21076
  • Herlev, Denmark|55.72366,12.43998

Key Eligibility Criteria

  • Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.
  • Signed written informed consent obtained prior to any study specific procedures.
  • Patient must be willing and able to comply with the protocol.
  • Biopsy proven locally advanced or metastatic renal cell carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →